Eplerenone Decreases Inflammatory Foci in Spontaneously Hypertensive Rat Hearts With Minimal Effects on Blood Pressure-Reference-Cited by-同舟云学术

Eplerenone Decreases Inflammatory Foci in Spontaneously Hypertensive Rat Hearts With Minimal Effects on Blood Pressure

Published:2009-01 Issue:1 Volume:53 Page:44-51
ISSN:0160-2446
Container-title:Journal of Cardiovascular Pharmacology
language:en
Short-container-title:

Author:

Brandish Philip E,Forest Thomas W,Chen Hongxing,Gatto Nicholas T,Molon-Noblot Sylvain,Zwierzynski Izabela,Szczerba Peter,Adamson Gary E,Ma Bennett K,Flores Osvaldo A,Hershey James C

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine,Pharmacology

Reference52 articles.

1. The new biology of aldosterone.;Connell;J Endocrinol,2005

2. Brain mineralocorticoid receptors: orchestrators of hypertension and end-organ disease.;Gomez-Sanchez;Curr Opin Nephrol Hypertens,2004

3. Aldosterone target organ protection by eplerenone.;Rudolph;Mol Cell Endocrinol,2004

4. Distinguishing the antihypertensive and electrolyte effects of eplerenone.;Levy;J Clin Endocrinol Metab,2004

5. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.;Pitt;N Engl J Med,1999

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease;Expert Opinion on Investigational Drugs;2015-06-20

2. Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury;Journal of Cardiovascular Pharmacology;2014-07

3. Targeting the mineralocorticoid receptor in cardiovascular disease;Expert Opinion on Therapeutic Targets;2013-01-17

4. SM-368229, a Novel Promising Mineralocorticoid Receptor Antagonist, Shows Antihypertensive Efficacy With Minimal Effect on Serum Potassium Level in Rats;Journal of Cardiovascular Pharmacology;2012-05

5. Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics;Molecular and Cellular Endocrinology;2012-03